SCHEMBL4774741

SCHEMBL4774741

COC(=O)c1ccc(NS(=O)(=O)CCc2ccccc2Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.58
PTGES2 Q9H7Z7 1/20 0.49
MAPT P10636 5/20 0.48
RAB9A P51151 3/20 0.48
LMNA P02545 2/20 0.47
NPC1 O15118 2/20 0.46
PLAU P00749 1/20 0.46
TSHR P16473 1/20 0.46
CDC25A P30304 1/20 0.44
CDC25B P30305 1/20 0.44
POLB P06746 2/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.42
ALOX12 P18054 1/20 0.42
KMT2A Q03164 1/20 0.42
PTPN1 P18031 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768066 0.85 PTGES2 (0.49) HPGDPTGES2MAPTRAB9ALMNA
SCHEMBL4777284 0.84 ACLY (0.49) HPGDPTGES2MAPTRAB9ALMNA
SCHEMBL4776613 0.83 HIF1A (0.50) HPGDPTGES2MAPTRAB9ALMNA
SCHEMBL4777693 0.81 HIF1A (0.54) HPGDPTGES2MAPTLMNACA1
SCHEMBL4771005 0.80 POLB (0.55) HPGDMAPTRAB9ALMNANPC1
SCHEMBL4772410 0.80 HIF1A (0.55) HPGDPTGES2MAPTPOLBCA1
SCHEMBL4776450 0.79 STAT3 (0.44) HPGDPTGES2MAPTRAB9ALMNA
SCHEMBL4770958 0.79 HIF1A (0.52) HPGDPTGES2MAPTTSHRCA2
SCHEMBL4771196 0.78 SMN1; SMN2 (0.53) PTGES2RAB9ANPC1L3MBTL1KMT2A
SCHEMBL4775262 0.78 MAPT (0.47) HPGDMAPTRAB9ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HPGD 2681/4885PTGES2 4324/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.